Anticoagulant-Related Nephropathy in a Patient with IgA Nephropathy [PDF]
, 2017 Anticoagulant-related nephropathy is a type of acute kidney injury caused by overcoagulation. We describe a case of an 84-year-old man with arterial hypertension, coronary heart disease and atrial fibrillation treated with acenocoumarol, who presented ...
Azevedo, A +3 more
core +1 more source
Journal of Health Economics and Outcomes Research, 2016 # Objective The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial ...
Carlos Rubio-Terrés +4 more
doaj +1 more source
Acenocoumarol – a historical overview and its place in modern anticoagulant therapy [PDF]
Българска кардиологияAcenocoumarol, a vitamin K antagonist (VKA), has played a pivotal role in anticoagulant therapy for over 60 years. Derived from the coumarin family, acenocoumarol inhibits vitamin K epoxide reductase, disrupting the synthesis of vitamin K-dependent ...
D. Farandzha
doaj +3 more sources
The relationships between vitamin K and cognition: a review of current evidence [PDF]
, 2019 Vitamin K is a fat-soluble nutrient discovered in 1935 and its role in blood coagulation has been thoroughly explored. In recent years, studies conducted in vitro and on animals highlighted vitamin K involvement in brain cells development and survival ...
Alisi, Ludovico +7 more
core +2 more sources
Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]
, 2017 A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto +2 more
core +4 more sources
Journal of IMAB, 2017 Purpose: Cardiovascular diseases are leading cause of mortality and disability worldwide. Major role in the treatment and prophylaxis of these diseases and their complications have antiplatelet and anticoagulation drugs.
Atanaska Dinkova +2 more
doaj +1 more source
The c.-1639g>A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use [PDF]
, 2009 Background/Aim. A single nucleotide polymorphism c.- 1639G>A in the promoter region of vitamin K-epoxide reductase (VKORC1) gene has been found to account for most of the variability in response to oral anticoagulants (OA). The aim of the study was to
Kovač Mirjana +3 more
core +1 more source
Pharmacogenomic testing and its future in community pharmacy [PDF]
, 2020 Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core +1 more source
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. [PDF]
PLoS Medicine, 2005 BACKGROUND: A C1173T polymorphism in intron 1 of the VKORC1 gene has been claimed to determine the interindividual variability in the response to vitamin K antagonist therapy (VKA), but it is unknown whether it also influences bleeding risk.
Pieter H Reitsma +4 more
doaj +2 more sources
An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials [PDF]
, 2019 Species differences in drug metabolism and disposition can confound the extrapolation of in vivo pharmacokinetic data to man, and also profoundly compromise drug efficacy studies due to differences in pharmacokinetics, in metabolites produced (which are ...
A. Rode +21 more
core +3 more sources